Navi Therapeutics (耐维思生物)
Shanghai ADC startup run by industry veterans, using AI-driven antibody and payload design for first-in-class conjugates.
1. Core Product / Service
Navi Therapeutics (耐维思生物医药（上海）有限公司) develops antibody–drug conjugates (ADCs). Its work spans antibody discovery, payload design, conjugation engineering and molecular optimization [1][2]. It has two named platforms:
- NaviMIG — a multispecific antibody platform.
- ReviLOAD — a payload platform.
The company describes its AI loop as "AI molecular design → experimental validation → data feedback → algorithm optimization" [1].
Pipeline. Two first-in-class ADCs for solid tumors are in preclinical development, with IND filings planned for the first half of 2027 [1][2]. Targets are not disclosed.
Wet-lab model: partly in-house, by the company's own description. Its platforms are said to cover antibody screening, linker-payload chemistry, site-specific conjugation and in vitro / in vivo efficacy testing [1]. That wording suggests the company does its own experiments, at least the decision-critical ones. Lab location, size and any CRO partners are not disclosed. Typical practice among Chinese startups of this stage is to keep key functional assays in-house and outsource bulk synthesis, GLP toxicology and CMC. Whether Navi follows that split is not confirmed.
2. Target Users & Pain Points
- Solid-tumor patients and oncology licensees. ADCs are one of the most active areas of China-to-global licensing. Differentiation now depends on new targets, multispecific formats and better payloads rather than another HER2- or TROP2-style asset. Navi's two platforms aim at exactly those gaps.
- Global pharma BD teams. The founders' track record is a large out-licensing deal (below), which points to an out-licensing exit model.
3. Competitive Landscape
| Player | Positioning | Vs. Navi |
|---|---|---|
| allink-biotherapeutics | Post-2023 Shanghai ADC / bispecific-ADC startup from a serial-founder team, two ADCs in global Phase I | Same cohort and modality, about 18 months ahead clinically; not positioned as AI-native |
| lingtai-tianrun | Post-2023 Shanghai ADC startup (autoimmune ADCs with non-steroid payloads, plus oncology) | Same cohort; already in Phase I and openly outsources payload-linker and GMP work to a CDMO |
| Duality Biologics, MediLink and other ADC platforms | Established Chinese ADC developers with global deals | Larger and clinical-stage; the bar Navi's FIC assets must clear in BD |
| aureka-bio | AI-designed functional / multispecific antibodies | Overlaps on AI-designed multispecifics; Aureka has much more capital and its own high-throughput lab |
| xtalpi / insilico-medicine | AI drug-discovery platforms that also partner on ADC design | Could serve as AI vendors to ADC developers like Navi |
4. Unique Observations
- "AI-native" is a matter of degree here. The founders are ADC drug developers, not AI researchers, and the AI staff are not named. AI looks like an enhancement to a conventional ADC biotech rather than the core engine. That still counts in the AI-native startup cohort, but at its industry-led end.
- Founding date is approximate. In August 2026 the company was described as "about a year and a half old", which implies a start around early 2025. The registration date has not been confirmed.
- The capital profile is that of a mainstream biotech. Legend Capital (君联) leading the A round, with the angel investors all following, is a standard Chinese biotech syndicate. It contrasts with the tech-fund-heavy syndicates behind anew-labs or aipher.
5. Financials / Funding
| Round | Date | Amount | Investors |
|---|---|---|---|
| Angel | not disclosed | not disclosed | Led by SANY Innovation (三一创新); Yuanhe Origin (元禾原点) and Fenglei (丰雷) followed [1] |
| Series A | Aug 2026 | not disclosed | Led by Legend Capital (君联); Kangjun Capital (康君) co-led; Yuansheng Ventures (元生创投) and others joined; all angel investors followed on [1][2] |
- Cumulative: "several hundred million RMB" across the two rounds [1][2]. Exact amounts are not disclosed.
- Use of funds: preclinical and IND-enabling work on the two ADCs, platform upgrades and hiring [1].
6. People & Relationships
- Co-founders: 韩佩 (Dr. Han Pei) and 黎玮 (Dr. Li Wei). Both previously led R&D and overseas out-licensing of a novel-target ADC program in a deal worth more than US$1B [1]. Their former employer is not named in the funding releases.
- Team: includes AIDD specialists, not named [1].
- Investors: Legend Capital, Kangjun Capital, SANY Innovation, Yuanhe Origin, Fenglei, Yuansheng Ventures.
- Peers: allink-biotherapeutics, lingtai-tianrun, aureka-bio, pinnacle-medicines.
Sources
- PEdaily — https://news.pedaily.cn/202608/567807.shtml
- ChinaVenture — https://m.chinaventure.com.cn/news/111-20260818-392809.html